Harnessing immune defense mechanisms has revolutionized cancer therapy, but our 29 understanding of the factors governing immune responses in cancer remains incomplete, limiting patient 30 benefit. Here, we use mass cytometry to define the organism-wide immune landscape in response to 31 tumor development across five tissues in eight tumor models. Systemic immunity was dramatically 32 altered across mouse models and cancer patients, with changes in peripheral tissues differing from those 33 in the tumor microenvironment and taking place in phases during tumor growth. This tumor-experienced 34 immune system mounted dampened responses to orthogonal challenges, including reduced T cell 35 activation during viral or bacterial infection. Disruptions in T cell responses were not cell-intrinsic but 36 rather due to reduced responses in antigen-presenting cells (APCs). Promoting APC activation was 37 sufficient to restore T cell responses to orthogonal infection. All systemic immune changes were reversed 38 with surgical tumor resection, revealing remarkable plasticity in the systemic immune state, which 39 contrasts with terminal immune dysfunction in the tumor microenvironment. These results demonstrate 40 that tumor development dynamically reshapes the composition and function of the immune 41 macroenvironment. 42 43 44 45 46 47 48
50
A plethora of immunotherapies and vaccines seek to elicit new immune responses in cancer patients, 78 yet no consensus has emerged for the cellular and molecular requirements to achieve this goal. In other 79 contexts, prior immune experience has important consequences for the response to new stimuli. Chronic 80 infection and inflammation impact immune responsiveness to novel challenges by shifting basal cytokine 81 levels, innate immune activation states, and overall lymphocyte composition [16] [17] [18] . A detailed assessment 82 of how tumor burden impacts responses to secondary immune challenges has yet to be performed, 83 despite the fact that many patients likely require new immune responses to benefit from 84 immunotherapies. It is also unclear whether there are lasting immune impacts after successful primary 85 tumor clearance. One study suggests that the accumulation of immunosuppressive myeloid cells in the 86 spleen rapidly alleviates with tumor resection 19 , highlighting a dynamic interaction between tumor burden 87 and immune state. Defining the functional capacity and stability of the tumor-experienced immune 88 macroenvironment is critical for improving immunotherapies. 89
The advent of high content single-cell analysis and corresponding analytical methods now allows us 90 to tackle the challenge of characterizing systems-level immune responses in cancer. Here, we defined 91 the systemic immune landscape in response to tumor development across eight commonly used mouse 92 models of cancer. These data, which are now publicly available, provide a rich resource for assessing 93 the relevance of any model to a particular question of interest or tumor type. While each tumor has 94 unique immunological consequences, we found that three distinct models of breast cancer converged on 95 similar changes to the systemic immune state. Tumor burden led to dynamic shifts in the organization 96 and functional capacity of immune cells across the organism, which culminated in attenuated responses 97 to secondary immune challenges. Tumor resection was sufficient to revert the systemic immune 98 landscape back to a healthy baseline. These findings have implications for how and when we apply 99 immunomodulatory agents in cancer, emphasizing the importance of strategies that are informed by 100 alterations in the immune macroenvironment. 101 102 Systemic immune organization is altered across multiple tumor types spanned genetically-engineered and transplantable syngeneic models across different mouse strain 105 backgrounds. We characterized a well-established, but pre-terminal tumor stage, to reflect the patient 106 populations most often treated with immunotherapies, but also to avoid the confounding impact of end-of-107 life processes. When tumors reached approximately 1 cm 3 in volume, we harvested the tumor along with 108 the blood, spleen, bone marrow, and tumor draining lymph node of each tumor-burdened animal and 109 healthy control littermate. We utilized mass cytometry to quantify the abundance and activity state of 110 immune cell subsets (Extended Data Table 1 The immune composition of the TME was distinct between tumor types, varying in the degree of 114 both immune infiltration and diversity ( Fig. 1a and Extended Data Fig. 2a ). The predominant immune cell 115 types in many tumors were tumor-associated macrophages and other CD11b high myeloid subsets, 116 particularly in the transplantable MC38 colorectal cancer and SB28 glioblastoma models. Interestingly, 117 both transplantable LMP pancreatic cancer and genetically induced Braf -Pten melanoma models showed 118 extensive eosinophil infiltration. B16-F10 syngeneic melanoma and three models of breast cancer 119 (transplantable cell lines 4T1 and AT3, and genetically induced MMTV-PyMT) showed less relative 120 abundance but much greater diversity in local immune cells, including B, T, and NK cell infiltration (Fig. 121 1a and Extended Data Fig. 2a ). The unique immune profiles across tumor types are reflected by PCA 122 (Fig. 1b) . 123 We next asked whether different tumors also resulted in distinct systemic immune landscapes. 124
The immune compositions of the tumor draining lymph node, bone marrow, blood, and spleen were 125 indeed altered, albeit to varying extents, across all tumor models ( Fig. 1c ). While varying in magnitude, 126 the breast cancer models consistently shifted together across principal component (PC) 2 in the lymph 127 node and PC1 in the bone marrow, blood, and spleen. Surprisingly, SB28 glioblastoma drove extensive 128 and distinct shifts in systemic immunity despite its localization in the CNS. Alterations in immune 129 composition in these peripheral sites did not correspond with local immune infiltrate. Thus, tumor burden 130 consistently drives changes in peripheral immune organization, highly dependent on the identity of the 6 tumor and distinct from the patterns of immune infiltration in the TME. 132
We next performed Statistical Scaffold Analysis to interrogate the impact of tumor burden on 133 individual immune cell types, focusing initially on the spleen as an example of a secondary lymphoid 134 organ with immune responses initiated distal from the tumor ( Fig. 1d and Extended Data Fig. 2b-f ). Our 135 approach enabled a detailed analysis of each major immune subset, building a complete picture of 136 tumor-driven immune reorganization. All models exhibited expansions in the splenic myeloid 137 compartment, which was dominant in some tumors, such as breast ( Fig. 1d ) but less dramatic in others, 138 such as melanoma (Extended Data Fig. 2e-f ). Extensive splenic remodeling in breast cancer was 139 specifically characterized by relative increases in neutrophils, eosinophils, monocytes, and plasma cells 140 and reductions of B and T cells ( Fig. 1d ). Again consistency was observed across breast cancer models, 141 which span three mouse strain backgrounds (BALB/c for 4T1, C57BL/6 for AT3, and FVB/N for MMTV-142
PyMT), both orthotopic injection and spontaneous tumorigenesis, and a range of metastatic potential. 143 Consistency despite these model differences argues strongly for a tumor and/or site-specific bias in 144 systemic immune responses. In line with the mouse models, gene expression analysis of whole blood 145 from untreated breast cancer patients and matched controls from the Norwegian Women and Cancer 146
Study demonstrated a marked shift in the immune state (PC1 Wilcoxon rank sum p-value = 5.0*10 -12 , 147 PC2 p-value = 1.6*10 -6 ) ( Fig. 1e ). Cellular enrichment analysis demonstrated increases in neutrophils 148 and plasma cells, as well as decreases in Th1 and CD8 T cells ( Fig. 1f ). Altogether, these data suggest 149 that tumor burden broadly drives distinct immune macroenvironments, providing context to inform 150 therapeutic manipulations designed to activate local versus systemic responses. 151 152
Tumor growth drives non-linear changes in immune cell frequencies over time 153
Tumors develop gradually, yet in the clinic tumors are sampled at one point in their development 154 to provide prognostic information related to the immune response. To understand the dynamics that 155 result in a given local and systemic immune response, we delved further into global immune remodeling 156 over time. Given the pronounced and consistent systemic immune changes observed in breast cancer 157 models, we focused on these tumor settings. We began our analysis of immune cell dynamics in an 7 orthotopic syngeneic model (4T1) due to its highly predictable kinetics before confirming results in an 159 unrelated spontaneous model (MMTV-PyMT). We first asked whether tumor-driven immune changes 160 developed discretely with tumor onset or progressively over tumor development. The absolute cell count 161 of tumor-infiltrating leukocytes also positively correlated with tumor growth, supporting a progressive 162 immune response (Extended Data Fig. 3a , r = 0.6, p = 0.0256). While absolute spleen cell counts 163 increased along with spleen size during tumor development, cell frequencies as a percent of total 164 leukocytes were comparable to absolute cell numbers per milligram of spleen tissue (Extended Data Fig.  165 3b). Thus, cell frequency was illustrated as the primary measure. Deep profiling of both the tumor and 166 splenic immune compositions by mass cytometry revealed nonparametric correlations in individual 167 cluster frequencies with time ( Fig. 2a-b ), demonstrating at the single cell level that immune changes are 168 indeed progressive. PCA of immune cell frequencies showed progressive changes across tissues over 169 tumor growth in both 4T1 ( Fig. 2c-d ) and MMTV-PyMT tumors (Extended Data Fig. 3c ). Importantly, the 170 immune profile within the TME remained distinct from those observed in peripheral sites. The draining 171 lymph node immune composition was unique, while coordinated changes were more apparent across the 172 spleen, blood, and bone marrow. Neutrophil expansion in the spleen and bone marrow, culminating in 173 elevated blood circulation, but lack of accumulation within the lymph node or tumor, is one feature 174 contributing to these unique profiles ( Fig. 2d ). 175
Progressive systemic immune responses to tumor burden were not strictly linear. Rather, unique 176 shifts in immune composition occurred at each analyzed time of tumor development. The magnitude of 177 change was non-uniform between each time point as evident by the PCA (Fig. 2c and Extended Data 178 Fig. 3c ). While some population changes were relatively continuous, such as increasing neutrophils or 179 decreasing CD4 + T cells, others were dynamic, like CD8 + T cells and Tregs, which reciprocally expanded 180 and contracted at distinct times in the tumor and draining lymph node (Fig. 2d ). To capture the behavior 181 of more specific immune cell clusters over time, we constructed Statistical Scaffold maps comparing 182 cluster abundances between each consecutive time point over 4T1 tumor growth (Extended Data Fig. 3d  183 and Extended Data Fig. 4 ). In the spleen, expansion within the myeloid compartment began by day 7 184 and continued to day 14, preceding the relative decline in the T and B cell compartments that became 185 evident by day 14 and continued through day (Extended Data Fig. 3d ). The lymph node also showed the 186 most dramatic immune changes by day 14 (Extended Fig. 4a ), while changes in blood were more 187 continuous (Extended Data Fig. 4b ). The bone marrow and tumor contained less mature and clearly 188 defined cell types, with many more inter-cluster connections and individualized patterns of change over 189 tumor growth (Extended Data Fig. 4c-d) . These data overwhelmingly demonstrate that the tumor immune 190 response is a highly dynamic process. T cell subsets that shifted with tumor growth ( Fig. 3b -c, Extended Data Fig. 5c-e ). The blood and spleen 205 profiles were more similar and dominated by CD4 + T cells. In contrast, the tumor T cell pool had more 206 shared subsets with the bone marrow, including an increasing double negative T cell population and a 207 decreasing NKT cell population with tumor progression ( Fig. 3c) . 208
Demonstrating the breadth of immune reorganization in cancer, all T cell clusters changed in 209 abundance across multiple tissues between early and late disease time points ( Fig. 3d ). Of particular 210 interest, tumor-infiltrating CD103 + Tregs, described as potent suppressors of effector T cells 22 , were 211 abundant at day 7 but decreased with tumor progression ( Fig. 3e ). This corresponded with CD103 + Treg 212 expansion selectively in the draining lymph node, suggesting that distal suppressive mechanisms may 213 support local changes to maintain a tumor-promoting systemic state. Anti-correlated changes extended 214 to conventional CD4 T cells, where CD44 + CD90 high activated CD4 T cells decreased in the tumor but 215 expanded in the lymph node (Fig. 3f ). The spleen showed the greatest change in CD44 + CD27 + memory 216 CD4 + T cells, which decreased with disease progression (Fig. 3g) . The blood showed expansion in 217 activated CD44 + CD4 + T cells expressing the CD31 adhesion receptor, which can promote T cell survival 218 in settings of inflammation ( Fig. 3h ) 23 . CD44+ CD8+ T cells expanding in lymph node expressed Ly6C 219 ( Fig. 3j ), which can support lymph node homing of central memory T cells 24 . CD8 + T cells generally 220 expanded in the tumor, but the most dominant cluster expressed high levels of PD-1 and CD69 221 previously associated with T cell dysfunction ( Fig. 3i ) 25, 26 . To explore the extent of dysfunction, we 222 interrogated intratumoral and splenic T cells for their expression of CD101 and CD38, two markers 223 recently identified as evidence of permanent T cell dysfunction 5 . Late-stage tumor burden led to 224 accumulation of CD38 + CD101 + CD8 + T cells in the tumor as expected; however, this phenotype did not 225 emerge in the spleen ( Fig. 3k ), suggesting that CD8 + T cells are altered differently in the TME and in the 226 We ran a similar pan-organ clustering analysis for the mononuclear phagocyte subsets (Extended 229 Data Fig. 6 ), and again found correlated and anti-correlated changes in cell states across sites with 230 tumor progression. As expected, the tumor-infiltrating subsets were very distinct from peripheral subsets 231 and expressed high levels of PD-L1. 232
We also specifically interrogated the expression dynamics of the PD-1 and PD-L1 immune 233 checkpoint proteins, the most commonly manipulated pathway by cancer immunotherapies to facilitate T 234 cell responses 27 . While expression of these molecules is used clinically for patient stratification, it 235 remains unclear whether they are expressed consistently or modulated dynamically over time. We 236 indeed found dynamic PD-1 and PD-L1 expression on infiltrating immune cells and non-immune cells of 237 the TME (CD45 -CD31 -) for both 4T1 and AT3 breast cancer models (Extended Data Fig. 7a-b ). Varied 238 expression over time held true in peripheral lymphoid organs, particularly the spleen and blood 239 (Extended Data Fig. 7c ). In fact, while the overall amount of PD-L1 expression was significantly less in 240 the blood compared to the tumor, median leukocyte signal intensity was strongly positively correlated 241 between these tissues (Extended Fig. 7d , r = 0.7487, p = 0.001). Both PD-1 and PD-L1 were 242 promiscuously expressed across immune cell types, particularly within the TME (Extended Data Fig. 7e ). 243
The most prominent cells expressing PD-L1 in the periphery were non-classical monocytes 28 and cDCs, 244 while PD-1 was abundantly expressed on T cells, neutrophils and eosinophils. Dynamicity in PD-1 and 245 PD-L1 expression suggests the potential for differential sensitivity to checkpoint blockade over the 246 course of tumor development. 247
One potential mechanism by which immune composition could be altered is a change in cellular 248 proliferation or death rates. By assessing Ki67 expression, we discovered that immune proliferation 249 indeed fluctuated systemically across breast cancer models (Extended Data Fig. 8a ). Changes in 250 proliferation were highly compartmentalized such that proliferation dynamics were unique to each site but 251 coordinated across all immune cell subsets within that site (Extended Data Fig. 8a-d ). We also measured 252 the expression of cleaved Caspase-3 to assess cell death and observed only minor changes in the 253 spleen (26 of 200 clusters changed significantly at day 14). Changes in Ki67 and cleaved caspase-3 254 expression corresponded poorly with clusters that were increasing or decreasing in frequency in the 255 spleen (Extended Data Fig. 8e ). Thus, while tumor burden systemically alters proliferation and death, 256 these processes alone likely do not account for the systemic immune alterations observed. 257
258
De novo T cell responses are impaired by pre-existing malignancy 259
Having established that tumor development drives an altered immune macroenvironment, we 260 determined whether immune responses to new challenges would be affected. Type 1 immune responses 261 are associated with strong cellular immunity and are generally thought to provide optimal anti-tumor 262 immunity. As model systems to understand how type 1 immune responses might take place in the 263 context of cancer, we challenged healthy or AT3 tumor-burdened mice with two well-described 264 pathogens that induce potent type 1 immunity, including CD8 + T cell proliferation and differentiation: 265 lymphocytic choriomeningitis virus (LCMV) and Listeria monocytogenes (Lm) 29,30 . Tumor-burdened mice 266 still cleared the pathogens from the spleen ( Fig. 4a-b ), consistent with the lack of complete 267 immunosuppression in solid tumor patients. However, the cellular immune response to infection was 268 dramatically altered. The composition of CD8 T cells was significantly altered in tumor-burdened mice 269 after infection, with marked reductions in short-lived and memory effector CD8 T cells ( Fig. 4c ). CD8 + T 270 cell proliferation was significantly abrogated under both infection conditions ( Fig. 4d ), along with impaired 271 cytotoxic capacity indicated by a reduction in Granzyme B production ( Fig. 4e ). Because strong CD8 + T 272 cell responses are paramount to effective anti-tumor immunity, this impairment of new cellular immunity 273 in the context of cancer presents a fundamental and unappreciated obstacle for immunotherapy. 274
We previously found that CD8+ T cells with markers of terminal dysfunction were only observed 275 in the TME and not the spleen (Fig. 3k ). Consistent with this hypothesis, splenic CD8 + T cells harvested 276 from either control or tumor-burdened animals were equally capable of producing the key effector 277 cytokines IFNγ, TNFα, and IL-2 in vitro (Extended Data Fig. 9a ). To test their functionality in the context 278 of infection, CD8 + T cells from OT-I transgenic mice expressing a high affinity T cell receptor specific for 279 ovalbumin (SIINFEKL) were isolated from control or tumor-burdened mice. We confirmed that AT3 280 tumors still drove systemic changes in TCR transgenic mice (Extended Data Fig. 9b ). These cells were 281 labeled with different fluorescent dyes to mark proliferation and were transferred together into healthy 282 recipient mice immediately prior to infection with Lm-expressing ovalbumin. OT-I CD8 + T cells from 283 control and tumor-burdened mice proliferated equivalently ( Fig. 5a ). However, when OT-I T cells were 284 transferred into tumor-burdened recipients prior to infection, they expanded poorly, failed to induce T-bet 285 expression associated with differentiation into effector cells, and expressed elevated levels of PD-1 ( Fig.  286 5b). Similar results were also observed when polyclonal CD8 T cells from control or tumor-burdened 287 mice were competitively transferred ( Fig. 5c ). These results demonstrate that cell extrinsic mechanisms 288 suppress systemic T cell activation and function in the tumor context. Importantly, they also suggest that 289 T cell behavior in vitro may not accurately predict their behavior once introduced into a tumor-burdened 290 host, bearing implications for adoptive T cell therapies. 291
Since tumor-experienced CD8 + T cells in the periphery were not dysfunctional, we hypothesized 292 that impaired APC activity earlier during the course of infection may contribute to decreased peripheral 293 CD8 + T cell activation. Dendritic cells (DCs) play a key role in orchestrating CD8 + T cell responses to 294
Lm 31 , and there is evidence to suggest that circulating DCs in breast cancer patients have reduced 295 antigen presentation 32 . Therefore, we quantified costimulatory molecule expression on splenic DCs 2 296 days post infection with Lm. We found that DCs from AT3 tumor-burdened animals expressed lower 297 levels of key costimulatory molecules CD80 and CD86 and the activation marker CD83 when compared 298 to healthy controls ( Fig. 5d and Extended Data Fig. 9c ). At a later time point coinciding with peak T cell 299 responses (day 7 post-infection), DCs from tumor-burdened mice continued to exhibit signs of 300 suboptimal activation, expressing lower levels of the adhesion molecule CD54 (ICAM-1) and PD-L1 301 (Extended Data Fig. 9d ). The latter result rules out the possibility that the PD-1/PD-L1 axis causes the 302 impairment in T cell responses and indicates that alternative strategies are likely required to induce new 303 systemic T cell activity. We therefore sought to pharmacologically boost APC activation as a plausible 304 strategy for achieving this goal. Anti-CD40 treatment drives potent and systemic APC activation as 305 shown by elevated CD86 and PD-L1 on splenic DCs ( Fig. 5e and Extended Data Fig. 9e ). In the context 306 of infection, anti-CD40 treatment rescued the defect in CD8 + T cell proliferation in tumor-burdened 307 animals 7 days post infection with Lm ( Fig. 5f ). At this time point, we also observed significantly higher 308 levels of activation markers CD54 and PD-L1 on DCs after treatment (Extended Fig. 9d ), consistent with 309 enhanced APC stimulation. In stark contrast, even high doses of IL-12p70 or treatment with anti-CTLA-4 310 failed to rescue T cell proliferation ( Fig. 5f and Extended Fig. 9f ), suggesting that T cell targeted 311 interventions alone are not sufficient. These experiments demonstrate that APCs fail to drive optimal new 312 T cell responses in the context of tumor burden. Furthermore, these data suggest that effective 313 immunotherapies should seek to boost APCs in combination with T cell focused treatments to fully 314 enable de novo immune responses. 315 316
Tumor resection reverses changes in systemic immune organization and responsiveness 317
Given that defects in T cell proliferation and differentiation were reversed when T cells were 318 removed from a tumor-burdened context, we asked whether tumor clearance was sufficient to revert all 319 changes in systemic immune organization and function. We performed surgical resection of tumors at a time when systemic changes were evident across sites and allowed mice to recover from surgery for an 321 additional 14 days to mitigate immune confounders from wound healing. We carefully tracked both local 322 recurrence and metastatic outgrowth by bioluminescent imaging. Impressively, we found that successful 323 tumor resection reversed changes in systemic immunity in both the AT3 and 4T1 tumor models ( Fig. 6a ). 324
Changes in both splenic immune cell frequencies and proliferative behavior became comparable to 325 control animals across tissues ( Fig. 6b -c, and Extended Fig. 10a-b ). PCA of all major cell frequencies 326 from both spleen and draining lymph node showed that resected animals closely resemble healthy 327 controls along the first principal component (PC1: 43% of the variance for AT3, 57% for 4T1) (Fig. 6d ). 328
Similarly, the composition of T cell clusters in the spleen and lymph node was also largely reverted after 329 resection ( Fig. 6e ). Finally, we asked whether the deficits in DC and T cell responses to infection were 330 alleviated with tumor resection. We observed higher CD86 and PD-L1 expression on DCs at day 7 after 331
Lm infection in resected mice, (Extended Fig. 10c-d ) and both T cell proliferation and Granzyme B 332 production after Lm infection were restored ( Fig. 6f-g ). Resected mice that had local or metastatic 333 recurrence again showed deficits in DC activation and T cell responses (Extended Fig. 10c Immunotherapies vary in efficacy across cancer types, showing success in melanoma patients 349 but only in a small subset of breast cancer patients 33 . Evidence of a strong pre-existing T cell response is 350 associated with clinical benefit from currently available immunotherapies. In the remaining majority of 351 cancer patients, it is likely that priming new immune responses will be required. Here, we show that 352 tumor burden causes varying degrees of disruption in systemic immune state across tumor types, which 353 is subtle in melanoma but dramatic in breast cancer. We demonstrate that severe disruptions in systemic 354 immunity in breast cancer impair de novo immune responses even to highly immunogenic pathogens. The ability of a tumor-burdened immune system to establish de novo immune responses is poorly 365 defined 36-38 , yet it is clearly essential for successful anti-tumor immunity against less immunogenic 366 tumors. Evidence exists that human cancer patients are more susceptible to opportunistic bacterial and 367 viral infections and also mount less effective immune responses to vaccination when compared to 368 healthy individuals 39, 40 . How much of this difference is attributable to systemic impacts of tumor burden 369 versus the effects of common cancer therapies has remained a matter of debate. We demonstrate that 370 immunity is indeed functionally impaired as a consequence of tumor development. The coordination of 371 adaptive immune responses to novel challenges that did not share antigens with the tumor was 372 significantly dampened. This striking observation challenges the idea that T cell dysfunction in cancer is 373 limited to tumor-specific T cells and driven largely by chronic antigen presentation. Instead, our data indicate impairment in the initial coordination of a T cell response by APCs, ultimately impacting T cell 375 proliferation and differentiation. It will be important to define the tumor-driven factors involved in failure of 376 APCs to effectively support T cell responses across different tumor contexts. 377
Finally, these studies reveal remarkable plasticity in the systemic immune state. Systemic 378 immune cells removed from the physiological context of the tumor responded normally to various 379 challenges in vitro and in vivo. Surgical tumor resection was sufficient to revert the systemic immune 380 landscape and function ability toward a healthy baseline. Tumor resection has previously been 381 associated with a reduction in myeloid-derived suppressor cells 19, 41 . Here, we extend these observations 382 to characterize in depth the extent to which the systemic immune state is reversibly impacted, in both 383 organization and in function. Influenced by the physiological immune context, immunotherapies will likely 384 have drastically different consequences when applied pre-or post-operatively. 385
This study demonstrates that tumor burden drives immune programs that reach beyond local Cells were resuspended in cell staining media (PBS with 0.5% BSA and 0.02% NaN3) and metal-labeled antibodies 458 against CD16/32 were added at 20 mg/ml for 5 min at RT on a shaker to block Fc receptors. Surface marker 459 antibodies were then added, yielding 500 uL final reaction volumes and stained for 30 min at RT on a shaker.
460
Following staining, cells were washed 2 times with cell staining media, then permeabilized with methanol for at 10 461 min at 4°C. Cells were then washed twice in cell staining media to remove remaining methanol, and stained with intracellular antibodies in 500 mL for 30 min at RT on a shaker. Cells were washed twice in cell staining media and 463 then stained with 1mL of 1:4000 191/193Ir DNA intercalator (Fluidigm) diluted in PBS with 1.6% PFA overnight.
464
Cells were then washed once with cell staining media and then two times with double-deionized (dd)H20. Care was 465 taken to assure buffers preceding analysis were not contaminated with metals in the mass range above 100 Da.
466
Mass cytometry samples were diluted in ddH2O containing bead standards (see below) to approximately 10 6 cells 467 per mL and then analyzed on a CyTOF 2 mass cytometer (Fluidigm) equilibrated with ddH2O. We analyzed 1-5*10 5 468 cells per animal, per tissue, per time point, consistent with generally accepted practices in the field.
470

Mass Cytometry Bead Standard Data Normalization
471
Data normalization was performed as previously described 6 . Briefly, just before analysis, the stained and 472 intercalated cell pellet was resuspended in freshly prepared ddH2O containing the bead standard at a 473 concentration ranging between 1 and 2*10 4 beads/ml. The mixture of beads and cells were filtered through a filter 10 1 10 2 10 3 10 1 10 2 10 3 10 4
